🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Peer Mentoring Intervention for HCV-Infected IDUs

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    phase 3 other completed

    1 trial

  2. Pegcetacoplan

    Apellis Europe B.V.

    Delayed Graft Function

    phase 3 small molecule active

    1 trial

  3. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

  4. Pegunigalsidase alfa

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    1 trial

  5. Pegvaliase

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule active

    2 trials

  6. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  7. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  8. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  9. Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. Pemigatinib

    Incyte

    Unresectable Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  11. Peramivir

    Biocryst

    Influenza

    phase 3 small molecule completed

    5 trials

  12. Peramivir

    Biocryst

    Seasonal Influenza

    phase 3 small molecule completed

    1 trial

  13. Peramivir 150mg

    Biocryst

    Influenza

    phase 3 small molecule terminated

    1 trial

  14. Peramivir+SOC

    Biocryst

    Cough

    phase 3 small molecule terminated

    1 trial

  15. Pergolide

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule completed

    1 trial

  16. Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  17. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion

    Hoffmann-La Roche

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  18. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection

    Fondazione Telethon ETS

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  19. Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.

    Hoffmann-La Roche

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  20. Physiotherapy

    United Therapeutics Europe Ltd

    Sciatica

    phase 3 other completed

    1 trial

  21. Picosulfate sodium, magnesium oxide, citric acid

    Universal Integrated

    Bowel Preparation Before Colonoscopy

    phase 3 small molecule completed

    1 trial

  22. Pimodivir 600 mg

    Janssen Cilag International NV

    Influenza A

    phase 3 small molecule terminated

    1 trial

  23. Pioglitazone

    Takeda

    Mild Cognitive Impairment Due to Alzheimer's Disease

    phase 3 small molecule terminated

    2 trials

  24. Pioglitazone

    Takeda

    HIV-Associated Lipodystrophy Syndrome

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources